Chemotherapy in the orthotopic xenograft model of TNBC.

The MDA-MB-231-BR3 cells expressing doxycycline-inducible shDNM2 or shGFP were used to create an orthotopic model of TNBC in Nu/Nu mice. The details of tumor inoculation and monitoring are provided in Supplemental Methods. Treatment began when tumors reached 60–90 mm³ and consisted of 2 cycles of cyclophosphamide or 1 cycle of cisplatin (300 mg/kg/cycle or 16 mg/kg/cycle, respectively). To induce DNM2 knockdown, doxycycline was given 3 days before and during cyclophosphamide or cisplatin administration. Cisplatin was given by i.p. injections on days 11, 13, 15, and 17 after tumor cell inoculations. Cyclophosphamide cycle was composed of 3 i.p. injections given every other day followed by a 2-week rest period.